Novo Nordisk A/S is to reorganize its R&D and split executive responsibilities for discovery and development following the retirement at the end of February of 30-year company veteran and current chief scientific officer Mads Krogsgaard Thomsen. He has been CSO of the Danish diabetes specialty company for the past 20 years.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?